FOLFOXIRI vs CapeOX before surgery for locally advanced rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial compares two chemotherapy plans given before rectal cancer surgery to see which helps more people and works better for disease control. If you have locally advanced rectal cancer and have not had treatment yet, this study may be an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal cancer that is adenocarcinoma, confirmed by pathology (lab testing of tissue)
- MRI shows your tumor is T3 or T4, or has lymph node involvement
- Your age is 18 to 75, and you’re well enough for treatment (ECOG 0–1)
- The tumor is close enough to the anus (within 15 cm) that surgeons may be able to remove it while preserving the anus
- You have not had any prior systemic chemo, radiation, or local procedure for rectal cancer
- Recent blood tests within 7 days are strong enough for chemotherapy and surgery (specific minimum counts and liver/kidney values)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
This trial compares a standard approach (chemotherapy and radiation before surgery) to a more intensive treatment (total neoadjuvant therapy plus radiation) for locally advanced rectal cancer. It aims to see if the stronger treatment helps remove the tumor and improves outcomes.
This trial tests whether adding two newer drugs to standard chemotherapy before surgery can shrink rectal tumors more effectively. It is for patients whose tumors are not too low in the rectum and have certain genetic markers.
This trial compares different combinations of chemotherapy drugs given before surgery to the standard approach of chemoradiation (chemotherapy plus radiation) for rectal cancer that has not spread. The goal is to see if the drug combinations are more effective at shrinking tumors and improving outcomes.
This trial tests whether combining chemotherapy (mFOLFOX6) and a short course of radiation before surgery improves outcomes for people with resectable rectal cancer. The goal is to shrink and control the cancer early and then remove it with curative surgery.
This Phase 3 trial compares two treatment plans given before rectal surgery. It tests whether stronger chemotherapy alone works better than chemotherapy pills plus long-term radiation to improve outcomes for locally advanced rectal cancer.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.